• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis.地舒单抗对比唑来膦酸治疗β-地中海贫血所致骨质疏松症患者。
Medicine (Baltimore). 2020 Dec 18;99(51):e23637. doi: 10.1097/MD.0000000000023637.
2
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.地舒单抗治疗输血依赖型地中海贫血性骨质疏松症：一项随机、安慰剂对照、双盲 2b 期临床试验。
Blood Adv. 2018 Nov 13;2(21):2837-2847. doi: 10.1182/bloodadvances.2018023085.
3
Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.每3个月与每年静脉注射唑来膦酸对低骨密度β地中海贫血患者的疗效回顾性比较
Med Arch. 2018 Jun;72(3):170-173. doi: 10.5455/medarh.2018.72.170-173.
4
Effects of bone remodeling agents following teriparatide treatment.骨重建药物对特立帕肽治疗后的影响。
Osteoporos Int. 2018 Jun;29(6):1351-1357. doi: 10.1007/s00198-018-4434-8. Epub 2018 Mar 14.
5
Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.地舒单抗与唑来膦酸治疗骨质疏松症起始后白内障手术和年龄相关性黄斑变性的风险：一项多数据库队列研究。
Drugs Aging. 2020 Apr;37(4):311-320. doi: 10.1007/s40266-020-00745-2.
6
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.地中海贫血所致骨质疏松症患者血清Dickkopf-1水平升高，且与骨密度降低相关。唑来膦酸治疗后该水平降低。
Haematologica. 2009 May;94(5):725-8. doi: 10.3324/haema-tol.2008.000893.
7
[Should we treat thalassemia-induced osteoporosis: two case reports].[我们应该治疗地中海贫血所致骨质疏松症吗：两例报告]
Praxis (Bern 1994). 2012 Oct 3;101(20):1325-9. doi: 10.1024/1661-8157/a001076.
8
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.唑来膦酸对β地中海贫血骨质疏松症患者骨转换标志物和骨密度的影响。
Ann Hematol. 2007 Jan;86(1):23-30. doi: 10.1007/s00277-006-0180-7. Epub 2006 Sep 30.
9
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
10
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.比较地舒单抗和唑来膦酸治疗实体瘤和多发性骨髓瘤伴骨转移：基于随机对照试验的系统评价和荟萃分析。
J Orthop Surg Res. 2021 Jun 22;16(1):400. doi: 10.1186/s13018-021-02554-8.

引用本文的文献

1
Treatment for osteoporosis in people with beta-thalassaemia.β-地中海贫血患者骨质疏松的治疗。
Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3.
2
Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.β 地中海贫血所致骨质疏松症的管理方法-重新审视长期存在的关系。
Acta Biomed. 2022 Oct 26;93(5):e2022305. doi: 10.23750/abm.v93i5.13668.
3
Curative Effect of Prebiotics/Probiotics Preparations Combined with Zoledronic Acid + Calcitriol Regimen on Patients with Primary Osteoporosis and Their Influences on Bone Metabolism Markers.益生元/益生菌制剂联合唑来膦酸+骨化三醇方案对原发性骨质疏松症患者的疗效及其对骨代谢标志物的影响
Emerg Med Int. 2022 Jul 21;2022:3293362. doi: 10.1155/2022/3293362. eCollection 2022.

本文引用的文献

1
Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.核因子κB受体活化因子配体抑制剂地诺单抗对重型β地中海贫血所致骨质疏松症的影响。
Indian J Endocrinol Metab. 2014 Jul;18(4):546-51. doi: 10.4103/2230-8210.137516.
2
Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment.重型地中海贫血中的骨质疏松症：最新进展及2013年国际地中海贫血专家共识会议关于监测与治疗的建议
Pediatr Endocrinol Rev. 2013 Dec;11(2):167-80.
3
Bone mineral density in thalassemia major patients from antalya, Turkey.土耳其安塔利亚地区的地中海贫血症患者的骨密度。
Int J Endocrinol. 2012;2012:573298. doi: 10.1155/2012/573298. Epub 2012 Jun 20.
4
Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism.迟发性男性性腺功能减退患者血清核因子κB受体活化因子配体和骨保护素水平升高。
Clin Invest Med. 2011 Aug 1;34(4):E232. doi: 10.25011/cim.v34i4.15365.
5
Bone mineral density in children with beta-thalassemia major in Diyarbakir.迪亚巴克尔地区重型β-地中海贫血患儿的骨密度。
Bone. 2011 Oct;49(4):819-23. doi: 10.1016/j.bone.2011.07.014. Epub 2011 Jul 23.
6
GH deficiency in adult B-thalassemia major patients and its relationship with IGF-1 production.成年重型β地中海贫血患者的生长激素缺乏及其与胰岛素样生长因子-1产生的关系。
Pediatr Endocrinol Rev. 2011 Mar;8 Suppl 2:284-9.
7
Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major.β-重型地中海贫血症成年患者经适当治疗后的内分泌和骨骼疾病。
Ann Hematol. 2010 Dec;89(12):1207-13. doi: 10.1007/s00277-010-1007-0. Epub 2010 Jun 26.
8
Direct effects of osteoprotegerin on human bone cell metabolism.骨保护素对人骨细胞代谢的直接作用。
Biochem Biophys Res Commun. 2009 Nov 20;389(3):550-5. doi: 10.1016/j.bbrc.2009.09.026. Epub 2009 Sep 11.
9
Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.骨保护素和核因子κB受体活化因子配体在重型地中海贫血患者骨质疏松发病机制中的作用
Panminerva Med. 2009 Mar;51(1):17-23.
10
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.双膦酸盐治疗对重型地中海贫血患者骨矿物质密度的影响。
Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:144-8.

地舒单抗对比唑来膦酸治疗β-地中海贫血所致骨质疏松症患者。

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis.

机构信息

Department of Medical Oncology/Hematology, National Centre for Cancer Care & Research (NCCCR).

Department of Laboratory Medicine and Pathology, Biochemistry Section.

出版信息

Medicine (Baltimore). 2020 Dec 18;99(51):e23637. doi: 10.1097/MD.0000000000023637.

DOI:10.1097/MD.0000000000023637
PMID:33371098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7748343/
Abstract

The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the bone densitometry by bone density(DEXA) scan as a standard of care by the radiology department, then a blood test for bone-specific alkaline phosphatase and type-1 collagen telopeptide will be measured by the chemistry laboratory.Patients with B-thalassemia major induced osteoporosis, who are 18 years of age or more and willing to participate in the study will be enrolled after consenting by the primary investigator in hematology outpatient clinics. Patients with osteoporosis will receive 1 of the 2 medications; at the end of the year, DEXA scan will be done to compare the response of the 2 medications. The potential risks include drug-related side effects.The outcome will be measured biochemically by measuring bone-specific alkaline phosphatase and type 1 collagen carboxy telopeptide and radiologically by DEXA scan at baseline and 1 year using Z score.

摘要

本研究的主要目的是比较两种药物地舒单抗和唑来膦酸在治疗β地中海贫血导致的骨质疏松症患者中的疗效。β地中海贫血导致的骨质疏松症患者将接受基线骨密度（DEXA）扫描评估，该检查由放射科作为标准护理进行，然后由化学实验室测量骨特异性碱性磷酸酶和 I 型胶原 C 端肽。在血液科门诊经主要研究者同意后，年龄在 18 岁及以上并愿意参加研究的β地中海贫血导致的骨质疏松症患者将被纳入研究。骨质疏松症患者将接受两种药物中的一种治疗，治疗 1 年后，进行 DEXA 扫描以比较两种药物的疗效。潜在风险包括药物相关的副作用。将通过测量基线和 1 年后的骨特异性碱性磷酸酶和 I 型胶原羧基端肽进行生化评估，并使用 DEXA 扫描进行影像学评估，以 Z 评分表示。